Login or sign up
For business

Bind therapeutics

3.7· 11 reviews
Average ratingAverage
3.7/ 5

Based on 11 reviews

518%
436%
345%
20%
10%
Orejobi Augustus
Reviews 1

Bind Therapeutics is an excellent company. Their innovative approach to drug delivery has the potential to revolutionize the field and improve the lives of countless patients. I am amazed by the results they have achieved so far and I am excited to see what the future holds!

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Bind therapeutics

They are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). To date in 2013, we have announced collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines.

Address
325 vassar street
Categories
Biotechnology